Dyadic International, Inc.

Good evening and welcome to DIDEX International First Quarter Fiscal 2022 Financial Results Conference Call. Currently, all participants are in listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this conference call is being recorded today, May 12, 2022. I would now like to turn the conference over to Ms. Ping Rawson, DIDEX Chief Financial Officer. Please go ahead.

Thank you. Good evening and welcome everyone to Dyadic International's first quarter 2022 conference call. I hope you have had the chance to review Dyadic's press release announcing financial results for the quarter ended March 31, 2022 and the recent company highlights. You may access our release and the Form 10-Q under the Investors section of the company's website at dyadic.com. On today's call, our president and CEO, Mark Imhoffar, will give a review of our first quarter's business and corporate highlights, including a brief summary of our research and business development efforts. Our chief business officer, Joe Hazleton, will join Mark for the business updates. I will follow with a review of our financial results in more detail. We'll then hold a brief Q&A session. Our senior management team will join for the Q&A session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause dyadic's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in DIATIC's reports filed with the SEC. It is now my pleasure to pass the call to our CEO, Mark Imelfarb. Mark?

Thank you, Ping. Hello, everyone, and thank you once again for joining DIATIC for our first update call of the new fiscal year. 2022 will be important for the development of Dyadic's business and our technologies. The foundation of Dyadic is our science, and advancement of that science has yielded a broad spectrum of business segments we can apply our technologies and experience to create revenue, profits, and long-term shareholder value. That value will be realized through the ability of Dyadic to help our customers develop more robust and efficient biomanufacturing processes. Dyadic remains laser-focused on our core life science business, where we are starting with infectious diseases. We continue to globally leverage the adoption of our C1 protein production platform to help speed the development and lower the cost of vaccines and antibodies. In our efforts to enhance our capability To drive shareholder value, we are also pursuing potential applications for our technologies in adjacent markets where we have a competitive differentiation. This effort is demonstrated by yesterday's announcement of our new collaboration agreement with a global food ingredients company for the manufacture of animal-free protein products. Over the past five years, we have successfully engineered our CM1 cells to where they are now being used to develop potential vaccines and treatments for a growing number of diseases to advance our life sciences applications. The adoption of C1 in infectious disease is growing, and DIATIC has multiple global research projects which continue to generate positive preclinical enamel data on several C1-produced antigens and antibodies. for hosts of infectious diseases, including influenza, rabies, SARS-CoV-2, Zika, and others. The primary objective of these projects is to validate the application of C1 as a differentiated biomanufacturing platform for developing and producing vaccines antibodies, and other therapeutics more rapidly at higher yields and lower costs for the prevention and treatment of infectious and other diseases such as oncology, arthritis, and diabetes. Earlier this week, we announced successful toxicology data published in Toxicologic Pathology. which demonstrates excellent safety profile and lasting immunogenic response from Diatix D1, DYA100 recombinant protein receptor binding domain RBD COVID-19 vaccine candidate. Since the beginning of this year, three manuscripts have been published in leading peer-reviewed scientific journals, which included scientists and authors from the EU, Israel, and the United States. These publications support that the scientific community is also recognizing the important role our C1 protein production platform may play in preventing and treating animal and human diseases. In furthering the validation efforts for our C1 platform, we intend to file our first in human clinical trial application, CTA, with the South African Health Products Regulatory Authority, SAFRA, to support the clinical safety of C1-produced proteins, including our DY-100 COVID-19 vaccine candidate. I will now turn the call over to our Chief Business Officer, Joe Hazelton, to provide a brief update on the progress of our Phase 1 program.